Gilde Healthcare's Buy & Build platform RAD-x acquires medical imaging group to initiate European expansion - Gilde Healthcare

Gilde Healthcare’s Buy & Build platform RAD-x acquires medical imaging group to initiate European expansion

January 24, 2017

RAD-x closes its first transaction: IRD SA, a leading Swiss Diagnostic Imaging Centre

RAD-x announced that it has acquired Geneva-based IRD SA, a leading diagnostic imaging provider. The sellers of IRD SA will reinvest part of the proceeds in the RAD-x holding and join the Gilde Healthcare Services II Fund and RAD-x management as shareholders of the group. IRD SA will continue to be managed by its founding doctors and with the help of RAD-x will invest in expanding its diagnostic capacity.

With this transaction, RAD-x kick-starts its growth model and positions itself as a contender in the fast consolidating European diagnostic imaging market. RAD-x’ operational model is focused on delivering high quality diagnostic imaging services to patients throughout Europe and its growth strategy is funded by Gilde Healthcare, a leader in healthcare private equity. RAD-x is in discussion with several other medical imaging and healthcare groups to expands its presence across Europe; by achieving a critical mass quickly, RAD-x will achieve better conditions in procurement for heavy medical equipment.

Martin HARDENS, Co-founder and CEO of RAD-x:

“I am pleased that we can welcome new partners in this early stage of development of RAD-x. This acquisition initiates our presence in the Swiss diagnostic imaging market. I look forward to working with the management team of IRD in delivering better healthcare for patients.”

Jasper van GORP, managing partner of Gilde Healthcare Services:

“RAD-x is a fast-growing leader with a first-class management team. In a consolidating market, Gilde has been impressed by RAD-x’ commitment to quality and efficiency towards patients and clinicians. We are confident in its capacity to achieve outstanding growth in RAD-x’ core international markets.”

Frank KOLO, Co-founder and Medical Director of IRD SA:

“I am confident that joining RAD-x will open new growth opportunities for IRD. Having a strong partner enables us to expand the diagnostic services we provide to our patients and referring doctors. RAD-x’ support for IRD to invest in two new state of the art MRI-machines and a refurbishment of our most important site is a proof of our joined commitment to continuous improvement in quality of care.”


Contacts:

Jasper van Gorp
Managing Partner
Gilde Healthcare
Tel. +31.30.219.2565
www.gildehealthcare.com

About RAD-x

RAD-x is a pan-European diagnostic imaging platform at the forefront of the outpatient radiology market consolidation in France, Germany and Switzerland. RAD-x’ management team has many years of experience executing radiology and laboratory Buy & Builds. RAD-x’ imaging centers are managed by independent healthcare professionals, all being partners of the group and using shared services to continuously improve their market leading quality and efficiency.
www.rad-x.eu

About Gilde Healthcare

Gilde Healthcare is a specialized European healthcare investor managing two business lines: lower mid-market buy-out funds (Gilde Healthcare Services) and venture & growth capital funds. The Gilde Healthcare Services Funds invest in profitable European healthcare services companies with a focus on the Netherlands, Belgium and Germany. Gilde’s venture & growth capital funds invest in medtech, diagnostics, digital health and therapeutics. Since 2001 Gilde Healthcare has raised €800 million ($900 million) for its specialized funds.
www.gildehealthcare.com

More news

Boston Scientific to Acquire Nalu Medical

We are pleased to announce the strategic exit of our portfolio company Nalu Medical. Boston Scientific, a global leader in medical technology, has agreed to acquire Gilde Healthcare portfolio company Nalu Medical at a $600m valuation....
October 17, 2025

Gilde Healthcare company Tagworks Pharmaceuticals Announces CTA Authorization and Initiation of Phase 0/1 Clinical Trial for TGW211, a Radiopharmaceutical for the Treatment of HER2+ Tumors

TGW211 is a next-generation, first-in-class HER2-directed radioimmunoconjugate developed based on Tagworks’ proprietary Click-to-Release – bioorthogonal, in vivo click chemistry – linker platform TGW211 is designed to achieve strong tumor uptake with selective and rapid elimination...
October 15, 2025

Gilde Healthcare company SpyGlass Pharma’s Novel BIM-IOL System Demonstrated a Statistically Significant Reduction in Mean IOP at 24 Months

42% reduction in mean intraocular pressure (IOP) compared to baseline (p<0.0001) 100% of patients were off all topical IOP-lowering medications at 24 months 100% of treated patients achieved 20/30 or better Best Corrected Distance Visual...
October 14, 2025